A recent study reveals that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass far faster than those who end traditional diet and exercise programs.
Research printed in a prominent health publication demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments need to be cognizant of the danger of rapid rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight in about 18 months.
Analyzing Therapies
The study, which examined dozens of trials involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
Scientists emphasize that individuals who lose weight through diet and exercise usually have a slower weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors propose the mechanism of the jabs explains the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making overeating much more probable."
A Chronic Issue?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts say that, due to the high risk of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the jabs explain a sudden return of appetite.
"It was like a trigger flipping and you're instantly extremely hungry," described an individual.
This challenge is exacerbated if users have not adopted permanent dietary or behavioural changes during therapy.
Growing Interest
Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with demand remaining high.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are effective agents for shedding pounds, they are not a magic fix and lasting health benefits relies on ongoing lifestyle support.
